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Background/Aims: The purpose of this study is to investi-
gate the recurrence rate of peptic ulcer disease (PUD) over a 
long follow-up period with PUD patients without Helicobacter 
pylori. Methods: We retrospectively reviewed patients diag-
nosed with PUD on endoscopy and divided them into two 
groups: a H. pylori-negative group (HP-negative group), and a 
group of patients with untreated H. pylori (HP noneradicated 
group). We compared the recurrence rates of PUD in these 
two groups and analyzed the factors that affected ulcer recur-
rence. Results: Total of nine hospitals in Korea participated, 
and a total of 1,761 patients were retrospectively reviewed. 
The HP-negative group included 553 patients, and the HP 
noneradicated group included 372 patients. The 5-year cu-
mulative probabilities of PUD recurrence were 36.4% in the 
HP-negative group and 43.8% in the HP noneradicated group 
(p=0.113). The factors that were found to affect recurrence 
in the HP-negative group were elder, male, and comorbid 
chronic kidney disease. Conclusions: The 5-year cumula-
tive probability of PUD recurrence without H. pylori infection 
after a long-term follow-up was 36.4% and the factors that 
affected recurrence were elder, male, and comorbid chronic 
kidney disease. (Gut Liver 2016;10:719-725)
Key Words: Natural course; Helicobacter negative; Peptic 
ulcer disease
INTRODUCTION
The most important cause of peptic ulcer disease (PUD) is 
Helicobacter pylori infection.1,2 Eradiating H. pylori aids PUD 
treatment and effectively reduces recurrence.3,4 The important 
causes of PUD other than H. pylori are gastric acid and drugs. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most 
important drugs, and antiplatelet agents, such as aspirin and 
steroids, are also considered to be possible causes of PUD.5,6 
Many factors other than H. pylori and NSAIDs affect PUD, but 
the influences of these factors are insignificant relative to H. 
pylori and NSAIDs. The successful eradication of H. pylori is the 
most important factor affecting the recurrence of PUD, although 
drugs, age, and the presence of chronic disease also affect recur-
rence.7-9
The recurrence rate of PUD with H. pylori infection decreases 
when H. pylori is successfully eradicated. Although the results 
vary between studies, the 5-year cumulative recurrence rate of 
PUD is below 5% if there is no risk factor due to NSAIDs and H. 
pylori is eradiated.10-12 There is a randomized controlled study 
with a 2-year follow-up of peptic ulcers without H. pylori infec-
tion, but this study does not mention recurrence because it was 
limited to duodenal ulcers, and the total number of enrolled pa-
tients was too small.13 The factors that affect the recurrence rate 
of peptic ulcers without H. pylori infection have not yet been 
studied.
Idiopathic peptic ulcer disease (IPUD) is defined by the pres-
ence of peptic ulcer without clear causes, such as H. pylori, 
NSAIDs, and hypergastrinemia. The incidence of IPUD varies 
from 1.3% to 27% due to variations in the H. pylori infection 
rate across different localities.14,15 Recently, the H. pylori infec-
tion rates have decreased in Korea, while the IPUD rates have 
increased. The clinical aspects of IPUD are more severe than 
PUD due to H. pylori and NSAIDs, and the recurrence rate is 
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higher.12,16-18 Moreover, the mortality and the risk of recurrent 
bleeding due to idiopathic bleeding ulcers are higher.19
The 5-year cumulative recurrence rate of IPUD was reported 
to be 24.3% in recent study, and this result is significantly high-
er than those for NSAIDs-induced PUD and eradicated H. pylori-
positive PUD.12 The long-term recurrence rate of PUD without H. 
pylori due to drug effects is assumed to be high; however, the 
evidence surrounding this issue is currently insufficient. H. py-
lori infection can be easily detected by several methods in PUD 
patients. However, smoking, alcohol, underlying disease, and 
drug history are frequently neglected or unknown. Although 
drug is a definite risk factor of PUD, because the duration and 
amount of drug are various, it is difficult to quantify its effect. 
Therefore, it is important to consider H. pylori infection status, 
the most effective and accurate measurable factor, as a predic-
tive factor of PUD recurrence rate. In the present study, we in-
vestigate the recurrence rate of PUD in a long-term follow-up of 
a cohort with PUD without H. pylori. To investigate the effects 
of H. pylori on the recurrence of PUD, we also examined the 
recurrence rate in H. pylori-positive PUD without eradication 
treatment. It is a well-known fact that H. pylori infection affects 
ulcer recurrence. However, our study focused on the recurrence 
rate of H. pylori negative ulcers. Additionally, we studied the 
patients’ drug histories and underlying diseases to identify the 
factors that affected the recurrence of PUD without H. pylori 
infection. 
MATERIALS AND METHODS
1. Patients
We studied PUD recurrence in patients who were diagnosed 
PUD based on esophagogastroduodenoscopy (EGD) in 2005 
and attended more than one follow-up visit. Total of nine hos-
pitals in Korea participated, and a total of 1,761 patients were 
retrospectively reviewed. PUD was defined by the presence of 
an ulcer larger than 5 mm including all active-, healing-, and 
scar-stage tissue. We excluded 242 patients who were initially 
diagnosed with PUD and followed up with EGD earlier than 6 
months after the initial diagnosis because it was unclear wheth-
er the disease was untreated or recurrent in these cases. We 
excluded 449 patients with histories of H. pylori eradication and 
54 patients with histories of partial gastrectomies, malignant 
ulcers, or malignancy within 5 years. We also excluded patients 
whose histories of smoking and alcohol use or underlying dis-
ease and drug histories were unclear. Ultimately, total 925 pa-
tients were enrolled this study.
Recurrent PUD was defined by the presence of an active-, 
healing-, or scar-stage ulcer in the stomach or duodenum 6 
months after the initial diagnosis. The location, stage, number, 
H. pylori infection status, and drug history were reviewed when 
recurrent PUD was identified. To discount untreated PUD, we 
excluded patients with scar-stage ulcers at the same locations as 
the initial events from the recurrent PUD group. 
This study was approved by the Institutional Review Board at 
The Catholic University of Korea (SC10RCME0191).
2. Characteristics and etiologic categorization of PUD
The locations, stages, and numbers of PUDs were investigated. 
When a PUD was confirmed on EGD, we also determined the H. 
pylori infection status based on more than one of the following: 
biopsy, rapid urease test (CLO test), and urea breath test. Once 
the H. pylori infection was confirmed, we checked for eradica-
tion. We also identified the smoking and alcohol consumption 
statuses, chronic diseases (cardiovascular, cerebrovascular, renal, 
liver, and pulmonary), and the possible association with PUD. 
The drugs that were considered risk factors (i.e., NSAIDs, aspirin, 
antiplatelet, and steroid) or protective (i.e., antacids, histamine 2 
receptor antagonists, proton pump inhibitors, and mucoprotec-
tive agents) were verified.
Table 1. Baseline Clinical Characteristics of the 925 Patients with 
Peptic Ulcer Disease 
Characteristic HP-negative HP noneradicated p-value
Number 553 372 -
Age, yr 58.5±13.7 55.5±12.7 <0.001
Male  299 (54.1) 222 (59.7) 0.092
Ulcer location 0.709
    Gastric ulcer  345 (62.4) 222 (59.7)
    Duodenal ulcer  158 (28.6) 114 (30.7)
    Gastric+duodenal 50 (9)  36 (9.7)
Ulcer stage 0.017
    Active stage 202 (36.5) 116 (31.2)
    Healing stage 199 (36.0) 173 (46.5)
    Scar stage 144 (26.0) 78 (21.0)
    Multiple stage 8 (1.4) 5 (1.3)
No. of ulcer 0.239
    Single 486 (87.9) 317 (85.2)
    Multiple 67 (12.1)  55 (14.8)
Smoking 82 (14.9)  68 (18.3) 0.166
Alcohol 117 (21.2)  69 (18.6) 0.325
Drug
    NSAIDs 28 (5.1)  23 (6.2) 0.465
    Aspirin 55 (10.0)  49 (13.2) 0.128
    Antiplatelet 19 (3.4)  19 (5.1) 0.209
    Steroid 15 (2.7)  4 (1.1) 0.085
No. of comorbid disease 0.655
    0 369 (66.7) 247 (66.4)
    1 147 (26.6) 105 (28.2)
    ≥2 37 (6.7) 20 (5.4)  
Data are presented as number (%) or mean±SD.
HP, Helicobacter pylori; NSAID, nonsteroidal anti-inflammatory drug.
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The patients were divided into the following two groups: (1) 
a H. pylori-negative group (HP-negative group) and (2) an un-
treated H. pylori-positive group (HP noneradicated group).
3. Statistical analysis
The statistical analyses were conducted using SAS version 
9.3 (SAS Institute, Cary, NC, USA). The baseline clinical char-
acteristics of the patients and the analyses of ulcer recurrence 
are pre sented as descriptive data. The continuous variables of 
the two groups are presented as the means±the standard devia-
tions and were tested with analyses of variance. The median 
values are presented for the variables that failed tests of normal-
ity, and the Kruskal-Wallis tests were applied to these variables. 
For the category-type variables, the ns (%) are presented, and 
chi-square and Fisher tests were applied. The cumulative prob-
abilities of ulcer recurrence were estimated with the Kaplan-
Meier method. The log-rank test was used to compare the time-
to-event curves of the two groups. Cox-proportional hazards 
model analyses were conducted to investigate the relationships 
of the recurrence of H. pylori-negative ulcers with the risk fac-
tors. The hazard ratios and 95% confidence intervals were esti-
mated after adjusting for age. The variables with p-values <0.15 
in the age-adjusted analyses were selected for the multivariate 
analyses. The p-values <0.05 were considered statistically sig-
nificant.
RESULTS
1. Baseline clinical characteristics
Among the 925 patients, 553 were included in the HP-nega-
tive group, and 372 were included in the HP noneradicated 
group (Table 1). The median age at the diagnosis of PUD of the 
HP-negative group was 58.5±13.7, which was greater than that 
of the noneradiated group (55.5±12.7, p<0.001). There were no 
differences between the two groups in terms of the other base-
line characteristics.
2. Analysis of follow-up
The mean follow-up duration in the HP-negative group was 
962 days, and the mean number of follow-up endoscopic pro-
cedures was 1.54 (Table 2). The mean follow-up duration in the 
HP noneradicated group was 1,028 days and the mean number 
of follow-up endoscopy procedures was 1.53.
Table 2. Analysis of the Follow-up Data and Ulcer Recurrence of the Two Groups
HP-negative HP noneradicated p-value
Duration of F/U, day* 962 (400–1,620) 1,028 (503–1,568) 0.274
Age of ulcer recurrence patient 63.2±14.3 56.5±14.0 <0.001
Ulcer recurrence rate 137 (24.8) 115 (30.9) 0.040
No. of additional endoscopy during F/U 1.54±0.76 1.53±0.76 0.813
Sex (male) of ulcer recurrence patient 82 (60.0) 79 (68.7) 0.146
Duration of ulcer recurrence* 518 (310–1,091) 685 (366–1,259) 0.238
No. of ulcer recurrence 0.097
    0 416 (75.2) 257 (69.1)
    1 123 (22.2) 102 (27.4)
    2 10 (1.8) 12 (3.2)
    3 4 (0.7) 1 (0.3)
Ulcer stage at recurrence 0.307
    Active stage 41 (29.9) 36 (31.3)
    Healing stage 62 (45.3) 56 (48.7)
    Scar stage 34 (24.8) 21 (18.3)
    Multiple 0 2 (1.7)
Gastric → gastric 73 (53.3) 61 (53) 0.688
Gastric → duodenal 20 (14.6) 14 (12.2)
Duodenal → duodenal 20 (14.6) 23 (20)
Duodenal → gastric 14 (10.2) 12 (10.4)
Multiple 10 (7.3) 5 (4.4)
Data are presented as number (%) or mean±SD.
HP, Helicobacter pylori; F/U, follow-up.
*Data are presented as median.
722  Gut and Liver, Vol. 10, No. 5, September 2016
3. Ulcer recurrence
The PUD patients were older because the HP-negative group 
was older in the baseline study. The rate of ulcer recurrence 
in the HP-negative group was 24.8%, which was significantly 
lower than that in the HP noneradicated group (p=0.040). The 
mean PUD recurrence duration in the HP-negative group was 
518 days. Males accounted for more than 60% of both groups, 
and these proportions were higher than those of the baseline 
study. 
In the HP-negative group, 24.8% of the patients experienced 
only one recurrence event, and 2.5% of the patients experienced 
more than two recurrence events. The most common stage of 
the recurrent ulcers was the healing stage (45.5%) followed by 
the active (29.5%) and scar stages (25%) with similar propor-
tions. The location (i.e., stomach or duodenum) of the recurrent 
PUD was the same as the original ulcer in 67.9% of the patients, 
and the majority of recurrence events were single ulcers (81.7%). 
The 5-year cumulative probabilities of PUD recurrence in the 
H. pylori-negative group and noneradicated groups were 36.4% 
and 43.8%, respectively (p=0.113). The difference of recurrence 
rate between of H. pylori negative to positive is no more than 2% 
until 3 year follow-up. However, the difference of recurrence 
becomes bigger when we follow the patients more than 3 years 
(Fig. 1).
4. Ulcerogenic factors 
Multivariate logistic regression analyses were performed to 
identify the factors that affected PUD without H. pylori infection 
(Table 3). Elder, male, and comorbid chronic kidney (CKD) dis-
ease were found to be risk factors. Smoking, alcohol, drugs, and 
other comorbid chronic diseases did not affect recurrence. The 
number of comorbid chronic disease did not affect recurrence.
Fig. 1. Kaplan-Meier estimates of the 5-year cumulative probabilities 
(95% confidence interval) and comparison of the recurrence of peptic 
ulcers in the two groups using a log-rank test.
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Table 3. Multivariate Logistic Regression Analyses of the Risk Factors for Ulcer Recurrence in the Patients with Helicobacter pylori-Negative Pep-
tic Ulcers
Age adjusted HR (95% CI)  p-value Multivariate HR (95% CI) p-value
Age, yr 1.033 (1.018–1.047) <0.001 1.031 (1.017–1.046) <0.001
Male sex 1.627 (1.151–2.299) 0.006 1.519 (1.027–2.247) 0.036
Smoking 1.539 (0.988–2.396) 0.057 1.453 (0.885–2.385) 0.140
Alcohol 1.142 (0.755–1.728) 0.530 - -
NSAIDs 1.302 (0.655–2.590) 0.452 - -
Aspirin 0.943 (0.519–1.713) 0.846 - -
Antiplatelet 0.502 (0.159–1.587) 0.241 - -
Anticoagulation 2.355 (0.578–9.597) 0.232 - -
Steroid 1.711 (0.796–3.678) 0.169 - -
No. of comorbid disease - 0.468 - -
Cardiovascular 1.154 (0.788–1.688) 0.462 - -
Cerebrovascular 0.733 (0.268–2.005) 0.545 - -
Liver 1.154 (0.668–1.992) 0.608 - -
Renal 2.057 (1.214–3.485) 0.007 2.026 (1.167–3.516) 0.012
Pulmonary 0.617 (0.225–1.69) 0.348 - -
Antacids 1.703 (1.187–2.444) 0.004 1.547 (0.988–2.422) 0.057
H2 receptor antagonists 1.461 (0.995–2.145) 0.053 1.297 (0.834–2.017) 0.249
Proton pump inhibitors 1.362 (0.95–1.954) 0.093 1.063 (0.694–1.63) 0.778
Mucoprotective agent 1.301 (0.892–1.897) 0.172 - -
HR, hazard ratio; NSAIDs, nonsteroidal anti-inflammatory drugs. 
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DISCUSSION
As H. pylori infection is the most important factor in the de-
velopment of PUD, H. pylori eradication can reduce the rate of 
PUD development. Various factors, including NSAIDs, can cause 
H. pylori-negative PUD. Various factors not only include modi-
fiable factors, such as drug and smoking, but also nonmodifi-
able host factors, such as age, sex, and chronic comorbid dis-
ease. It is important to predict the recurrence rate of H. pylori-
negative PUD by these various factors, especially in countries 
where H. pylori infection rate is low.
This study retrospectively reviewed patients with PUD during 
962 days, in average, up to 10 years to investigate the recur-
rence rate of PUD without H. pylori infection and the associated 
risk factor. The H. pylori-positive infection rate at baseline was 
60.3%, which is similar to the previously reported H. pylori 
infection rates in Korea.9 The recurrence rate of PUD without 
H. pylori infection was higher, and the symptoms were more 
severe compared with the results of a previous study that in-
vestigated H. pylori-positive PUD patients who had undergone 
eradication.13 However, the interpretation of the recurrence rate 
reported in that study is limited because the total number of en-
rolled patients was too small. In the present study, 24.8% of the 
553 patients with PUD without H. pylori infection experienced 
recurrence, and the 5-year cumulative probability of recurrence 
was 36.4%. The 5-year cumulative recurrence rate of idio-
pathic ulcers has previously been reported to be 24.3%, which 
is lower than the rate observed in the present study.12 There are 
three possible interpretations of this difference in recurrence 
rates. The first involves the possible effects of drugs, including 
NSAIDs, on PUDs, in patients without H. pylori infection. The 
second involves the calculations of the recurrence rates; unlike 
the other study, we included the scar-stage of PUDs that were 
present 6 months after the initial diagnoses in the calculation of 
the recurrence rate. The inclusion of scar-stage ulcers in recur-
rence is controversial. Depending on the investigator, there is 
a wide variation regarding this issue. Normal findings can be 
mistaken for scar-stage ulcers, and scars from previous PUD 
can be mistaken for recurrent ulcers. However, it is difficult to 
determine whether recurrence has occurred because small PUDs 
with nonsevere mucosal defects have no symptoms and with-
out bleeding or symptoms can be mistaken for other diseases.20 
The majority of PUD cases are cured within 6 months; thus, 
it is appropriate to include scar-stage ulcers present 6 months 
after the initial diagnosis in the recurrence rate calculation. The 
third involves that we almost all diagnosed H. pylori using one 
single method. Because of these conditions, it may be possible 
that ulcers that were diagnosed as H. pylori negative may actu-
ally were H. pylori positive. As a consequence, the recurrence 
rate may has been measured higher than that of other previous 
report. To complement these data, we studied in a large number 
of patients, more than 900.
The location (i.e., stomach or duodenum) of the recurrent 
PUD was the same as the original ulcer in 67.9% of the patients. 
83.9% of H. pylori-positive PUD had PUD recurrence at the 
same location after eradication therapy.8 Although the mecha-
nism between stomach and duodenum ulcer development is 
different, H. pylori plays an important role in both cases. The 
reason why the percentage of recurrent PUD at different loca-
tion is more than 30% higher in H. pylori-negative PUD is be-
cause other risk factors, besides H. pylori, react through various 
pathways at different locations.
As mentioned above, it is difficult to quantify the effect of 
other PUD risk factors. However, it is certain that risk factors 
other than H. pylori and including NSAIDs, play an important 
role in H. pylori-negative PUD. In this study, we examined the 
factors that affect the recurrence of H. pylori-negative PUD. 
Age, sex (male), and comorbid CKD were the risk factors, which 
were all nonmodifiable factors. Modifiable factors, such as 
smoking and drug were not risk factors of recurrence.
Age is an important factor in the occurrence and recurrence 
of PUD regardless of H. pylori infection.7,9 With aging, the blood 
supply to the gastric mucosa decreases, prostaglandin levels de-
crease, and mucosal defense weakens. These factors are known 
to be mechanisms of ulcer development. In previous research, 
patients with PUD without H. pylori infection have been found 
to be older,18,21-24 and the mean age of the PUD patients with-
out H. pylori infection patients was greater than that of the H. 
pylori-positive patients at both baseline and recurrence in the 
present study. H. pylori is the most important cause of ulcer de-
velopment in PUD with H. pylori infection, and the weakening 
of the gastric mucosal defense cause of recurrence. Therefore, 
the PUD recurrence rate of older PUD without H. pylori infec-
tion patients is high, and more active treatment and follow-up 
is necessary for these patients. 
In addition to age, the male sex and the presence of CKD 
are related to PUD recurrence. In Korea, although male was a 
risk factor of PUD development, it was not related recurrence.9 
However, in this study, male was also a risk factor of recur-
rence in H. pylori-negative PUD. Although the mechanism that 
CKD develops PUD is not known, increased gastrin level and 
gastric acid hypersecretion may be relevant to the pathology. In 
other studies, the H. pylori infection rate among PUD patients 
with CKD has been found to be lower than that of non-CKD 
patients.25 Based on these studies, the ulcerative effect of CKD is 
presumable more dramatic in H. pylori-negative patients than H. 
pylori-positive patients. In this study, we did not divide CKD by 
stages. It would be helpful to confirm ulcerogenic effect of CKD 
by investigating the relationship between PUD and CKD stages.
In the present study, the other possible causes of H. pylori-
negative PUD, such as smoking, alcohol use, and comorbid 
diseases other than CKD, were not found to be related to recur-
rence.
The most important causes of PUD without H. pylori are 
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NSAIDs and aspirin. NSAIDs reduce the synthesis of prosta-
glandins and cause toxic injury by inhibiting cyclooxygenase 
1 (COX-1). In the present study, ulcer-aggravating drugs (i.e., 
NSAIDs, aspirin, steroids, and antiplatelet drugs) were not found 
to affect PUD recurrence because the drug histories were re-
viewed at the baseline time point and not at the time point of 
recurrence or because the patients with NSAID-induced PUD 
stopped taking NSAIDs or switched to cyclooxygenase 2 (COX-2) 
inhibitor medications.
Proton pump inhibitors are important drugs in the treatment 
of PUD, and the recurrence of PUD among NSAID-induced PUD 
patients who cannot stop taking NSAIDs can be reduced with 
proton pump inhibitors. In the present study, ulcer-protective 
drugs were investigated when recurrence occurred, but they 
were not found to affect the recurrence rate. We investigated 
whether the patients were taking such medicines, but the du-
rations of medicine use were not accurately investigated. To 
investigate whether ulcer-protective drugs affect recurrence, the 
duration of the dosing period and the concomitant history of 
ulcer-aggravating drugs should be investigated.
The strengths of this study were that the total number of en-
rolled PUD patients without H. pylori infection (553) was greater 
than those in previous studies and the follow-up duration was a 
maximum of 10 years, which is longer than the follow-ups that 
have been employed in previous research.
The limitations of this research are the retrospective nature of 
the study and that endoscopic follow-ups were not performed. 
Endoscopic procedures were performed more frequently when 
symptoms were present, which might have affected the results. 
However, we overcame this limitation by including the scar-
stage ulcers in the recurrence rate calculations. An additional 
shortcoming of this multicenter study is the fact that the diag-
nostic PUD criteria varied across the centers. The final limitation 
is that the durations of medicine use were unclear, which is a 
limitation in terms of the effects of ulcer-protective and aggra-
vating drugs. Moreover, the recurrence rate of H. pylori negative 
ulcer may has been measured higher than other studies because 
we included the effect of ulcer aggravating drugs, whereas other 
studies eliminated these conditions. A prospective study is need-
ed to accurately estimate the effect of drug in the recurrence of H. 
pylori-negative PUD.
In conclusion, the 5-year cumulative probability of PUD re-
currence without H. pylori infection after a long-term follow-
up was 36.4%, which is higher than that reported in a previous 
study, and the factors that affected recurrence were elder, male, 
and comorbid CKD.
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